BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Exclusion Criteria

• •1. Contre-indications for cytotoxic treatment according to the Summary of Product Characteristics (Arm B).
• •2. Clinical evidence of active brain metastasis or leptomeningeal involvement.
• •3. Other malignancy currently requiring active therapy.
• •4. QTc prolongation according to Fridericia formula deemed clinically relevant by the investigator (e.g., congenital long QT syndrome, QTc according to Fridericia formula \> 470 ms).
• •5. Hypersensitivity to one of the trial drugs or the excipients.
• •6. Serious illness or concomitant non- oncological disease.
• •7. Systemic anticancer therapy within 4 weeks before the start of the study.
• •8. Evidence of ileus sor sub ileus.